search
Back to results

Evaluation of a Local Preconditioning Effect in Patients Undergoing Cardiac Surgery

Primary Purpose

Heart Disease, Coronary Artery Bypass Graft Triple Vessel

Status
Terminated
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
PICSO
Sponsored by
Medical University of Vienna
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Disease

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients of either sex and between 18 and 85 years of age scheduled for surgery without severe confounding disease will be asked to participate in the study.
  • Written informed consent will be obtained in eligible patients.

Exclusion Criteria:

  • Patients with unstable angina pectoris and/or myocardial infarction within the last 30 days, as well as persons with planned concomitant valvular interventions will be excluded. Patients with malignoma, severe hepatic, renal and pulmonary disease will also be excluded

Sites / Locations

  • Medical University of Vienna

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

PICSO

Control

Arm Description

PICSO (pressure controlled intermittent coronary sinus occlusion), a special coronary sinus catheter will be introduced after induction of anaesthesia until going on bypass.

normal procedure of preparing Bypass grafts. Equivalent time before going on Bypass is determined as control period

Outcomes

Primary Outcome Measures

Reduction in enzyme leakage measured by AUC.
Enzyme leakage (Troponin T, CK-MB) will be measured preoperatively, at the beginning of the operation, the beginning of ECC at the time of reperfusion the arrival on the ICU and 6,12,24,48 and 72 hours postop and the area under the curve will be calculated (AUC until 72 hours). Study Hypotheses: PICSO reduces troponin T leakage about 30 % measured by AUC until 72h in comparison to controls. PICSO improves 30d and long-term outcome

Secondary Outcome Measures

Combined endpoint of major adverse cardiovascular events (MACE) and mortality after 30 days.
N-terminales pro brain natriuretic peptide (NT-pro BNP) values at 1 day pre-surgery as well as 30d and 6 months post-operative
Pre-operative (1d) as well as post-operative (6, 12, 24, 48, 72 h, 30d) C-reactive protein (CRP) measurements

Full Information

First Posted
November 29, 2011
Last Updated
April 6, 2015
Sponsor
Medical University of Vienna
search

1. Study Identification

Unique Protocol Identification Number
NCT01482780
Brief Title
Evaluation of a Local Preconditioning Effect in Patients Undergoing Cardiac Surgery
Official Title
EASY-TRIAL: Evaluation of a Local Preconditioning Effect in Patients Undergoing Cardiac Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Terminated
Why Stopped
Logistic reasons, lack of funding
Study Start Date
March 2012 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
March 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Vienna

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the study is to analyze the potential of pressure controlled intermittent coronary sinus occlusion (PICSO) to prevent/reverse the ischemic burden as well as reperfusion injury. To achieve insight into the clinical significance of this local preconditioning effect, global hemodynamics, cardiac performance and clinical outcome in the first 30 days will be related to the ability of this intervention to protect the myocardium in elective surgical procedures, ameliorating cellular decay and preserving the microcirculation therefore improving graft flow, reducing enzyme leakage and finally improving myocardial performance.
Detailed Description
Patients undergoing elective coronary artery bypass graft (CABG) will be enrolled in this study. A computerized randomization process is used to obtain similar distributions within each group. Stratification will be done by the severity of coronary artery disease, age and sex. Routine blood sampling will be performed the day before surgery as well as a transthoracic echocardiography (TTE) study to determine ventricular volumes and valvular function. A modified Minnesota quality of Life questionnaire will be assessed and these data will be compared with 30 days outcome data screened in an outpatient environment. A 12 lead electrocardiogram will be obtained. To assess eligibility and to assure grouping (stratification & randomization) patients will be scored using the additive EuroSCORE. Pre-, intra-, and postoperative (up to 72 hrs) measurements of myocardial enzyme leakage will be performed using standard diagnostic procedures (cardiac troponin T, CK-MB, and total creatine kinase), as well as serial electrocardiograms and echocardiograms. Perioperative infarction will be assessed as the development of new persistent regional wall motion abnormalities in echocardiography together with electrocardiographic alterations and CK-MB increases and new Q-wave PMI. Sequential cytokine analyses (IL-1, IL-6, IL-8, IL-10, IL-17, VEGF and TNF- alpha ) preoperatively, at the beginning of the operation, the beginning of ECC and 6,24 h and 30 days postop. Serial quantification of global and regional wall motion will be recorded using TEE measurements during surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Disease, Coronary Artery Bypass Graft Triple Vessel

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PICSO
Arm Type
Experimental
Arm Description
PICSO (pressure controlled intermittent coronary sinus occlusion), a special coronary sinus catheter will be introduced after induction of anaesthesia until going on bypass.
Arm Title
Control
Arm Type
No Intervention
Arm Description
normal procedure of preparing Bypass grafts. Equivalent time before going on Bypass is determined as control period
Intervention Type
Device
Intervention Name(s)
PICSO
Other Intervention Name(s)
PICSO, Miracor medical Systems, Austria
Intervention Description
PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
Primary Outcome Measure Information:
Title
Reduction in enzyme leakage measured by AUC.
Description
Enzyme leakage (Troponin T, CK-MB) will be measured preoperatively, at the beginning of the operation, the beginning of ECC at the time of reperfusion the arrival on the ICU and 6,12,24,48 and 72 hours postop and the area under the curve will be calculated (AUC until 72 hours). Study Hypotheses: PICSO reduces troponin T leakage about 30 % measured by AUC until 72h in comparison to controls. PICSO improves 30d and long-term outcome
Time Frame
72 hours postop
Secondary Outcome Measure Information:
Title
Combined endpoint of major adverse cardiovascular events (MACE) and mortality after 30 days.
Time Frame
30 days
Title
N-terminales pro brain natriuretic peptide (NT-pro BNP) values at 1 day pre-surgery as well as 30d and 6 months post-operative
Time Frame
30 days
Title
Pre-operative (1d) as well as post-operative (6, 12, 24, 48, 72 h, 30d) C-reactive protein (CRP) measurements
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients of either sex and between 18 and 85 years of age scheduled for surgery without severe confounding disease will be asked to participate in the study. Written informed consent will be obtained in eligible patients. Exclusion Criteria: Patients with unstable angina pectoris and/or myocardial infarction within the last 30 days, as well as persons with planned concomitant valvular interventions will be excluded. Patients with malignoma, severe hepatic, renal and pulmonary disease will also be excluded
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Werner Mohl, DDr
Organizational Affiliation
Medical University of Vienna, Abteilung für Herz-, Thoraxchirurgie
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Werner Mohl, DDr.
Organizational Affiliation
Medical University of Vienna
Official's Role
Study Director
Facility Information:
Facility Name
Medical University of Vienna
City
Vienna
ZIP/Postal Code
A-1090
Country
Austria

12. IPD Sharing Statement

Learn more about this trial

Evaluation of a Local Preconditioning Effect in Patients Undergoing Cardiac Surgery

We'll reach out to this number within 24 hrs